Orion announces agreement with Shilpa Medicare for Recombinant Human Albumin for European market ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

The gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by Outlook Therapeutics are expected to be approximately $13.0 million.

Founded in Granbury, Texas, Revolver Brewing has built its reputation on pushing boundaries while staying true to its roots.

AB Science S.A. (the “ Company ” or “ AB Science ”, Euronext – FR0010557264 – AB) today announces the settlement and delivery of its capital increase announced on May 20, 2025 for an amount of €1.8 ...

The strategic collaboration with Broad Clinical Labs will explore and develop applications using Roche’s SBX sequencing technology1, with an initial focus on critically ill newborns and their parents.

On January 29, 2025, Inventiva announced the publication in Journal of Hepatology of the results of the investigator-initiated proof-of-concept clinical trial led by Dr. Kenneth Cusi, demonstrating ...

Updated data from the pivotal phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a Basel, 23 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) ...

Jefferies is acting as lead book-running manager for the offering and H.C. Wainwright & Co. is acting as co-manager for the offering. Gyre intends to use the net proceeds from this offering, together ...

NIC is a Canadian company which has the exclusive master franchise rights from NoBrainer Alzheimer’s Treatment Centers, Inc. (“NATC”) for the Canadian market (with the exception of the cities of ...

Conference: LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar Date/Time: Thursday, May 29 th at 2:40 PM ET Presenter: Timothy Lu, M.D., Ph.D. Co-Founder and Chief Executive ...

Updated results of fruquintinib combined with PD-1 inhibitors and chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma (FDZL-FIX): a ...